# PT-141 (bremelanotide, Vyleesi)

Source: https://aminodesk.com/library/pt-141
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

PT-141 is the research name for bremelanotide, which the FDA approved in 2019 as Vyleesi. The approval is narrow: low sexual desire in premenopausal women. It is not approved for men, for postmenopausal women, or to improve sexual performance.

- **Legal lane:** FDA-approved, prescription only
- **Evidence grade:** A for its approved use
- **Form:** single-dose autoinjector, used as needed
- **Brand:** Vyleesi

## What it is

Bremelanotide activates melanocortin receptors in the brain, the same receptor family that [Melanotan II](https://aminodesk.com/library/melanotan-ii) acts on. It was developed from that line of research, which is why it shares some of the same side effects, including skin darkening.

## What the evidence shows

Approval rested on two identical Phase 3 trials, called RECONNECT, in about 1,250 premenopausal women with acquired low sexual desire. Over 24 weeks, bremelanotide improved desire scores and reduced distress about low desire compared with placebo, and a 52-week open-label extension found the improvement held.

The effect was measured on questionnaires. An editorial published alongside the trials noted that the studies did not show an increase in the number of sexual events.

## Dosing on the label

- 1.75 mg injected under the skin of the abdomen or thigh, as needed, at least 45 minutes before expected sexual activity.
- No more than one dose in 24 hours.
- No more than 8 doses a month.
- Stop after 8 weeks if there is no improvement.

The vials of "PT-141" sold online are the same molecule in unregulated powder form. Their purity and content are unverified, and nothing about men or daily use has been established by the trials above.

## Side effects and warnings

- **Nausea** is the most common side effect and the main reason people stopped in trials, usually after the first dose. Flushing and headache were also common.
- **Blood pressure:** each dose raises blood pressure and lowers heart rate for several hours, usually back to normal within 12 hours. It is contraindicated with uncontrolled high blood pressure or known heart disease.
- **Skin darkening:** patches of darker skin on the face, gums or breasts appeared in 1% of trial patients at up to 8 doses a month, and in 38% of people in a study of daily dosing for 8 days. It did not always fade after stopping.
- **Naltrexone:** it can sharply reduce absorption of oral naltrexone, which matters for anyone taking it for alcohol or opioid addiction.

## Common questions

### What is PT-141 approved for?

As Vyleesi, it is FDA-approved for low sexual desire in premenopausal women. It is not approved for men or for postmenopausal women.

### What is the Vyleesi dose?

The label dose is 1.75 mg injected under the skin as needed, at least 45 minutes before expected sexual activity. The limits are one dose in 24 hours and 8 doses a month.

### What are the side effects of PT-141?

Nausea is the most common, along with flushing and headache. Each dose raises blood pressure for several hours, and patches of darker skin appeared in 1% of trial patients.

Added in the latest update. These answers summarize the sections above; sources are listed below.

## Sources

- [FDA label: Vyleesi (bremelanotide), 2019](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf)
- [Kingsberg et al. 2019: the two RECONNECT Phase 3 trials, Obstetrics & Gynecology (PubMed)](https://pubmed.ncbi.nlm.nih.gov/31599840/)
- [Simon et al. 2019: 52-week open-label extension (PubMed)](https://pubmed.ncbi.nlm.nih.gov/31599847/)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
